Biotechnology Company Completes $3M Private Placement of Series A Voting Convertible Preferred Stock

A private biotechnology company completed a $3 million private placement of Series A voting convertible preferred stock. Our firm represented the biotechnology company, which specializes in the treatment of cancer.

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.